药物诱发大疱性类天疱疮  

Drug-induced bullous pemphigoid

作　　者：刘冰[1] 左亚刚[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院皮肤科,北京100730

出　　处：《国际皮肤性病学杂志》2012年第4期235-238,共4页International Journal of Dermatology and Venereology

基　　金：国家自然科学基金（81071301）;教育部新世纪优秀人才计划（NCET-10-0964）

摘　　要：药物诱发大疱性类天疱疮是一种由于系统及局部用药诱发的以水疱大疱为主要表现的自身免疫性疾病。其诱导药物种类繁多，包括抗生素、利尿剂、血管紧张素转化酶抑制剂等。其发病机制尚不完全清楚，但与经典的大疱性类天疱疮不同，各种药物导致疾病发生的机制亦不完全相同。本病与经典大疱性类天疱疮在临床表现方面有一定区别，但实验室检查相似。因此，临床中应注意大疱性类天疱疮患者潜在的药物诱发因素，并及时停用诱发或可疑药物。Drug-induced bullous pemphigoid （DIBP） is a kind of autoimmune bullous disease caused by systemic or local use of drugs and characterized by vesicles and bullae. The causative drugs are various, including antibiotics, diureticum and angiotensin converting enzyme inhibitors, etc. The pathogenesis is unclear at present, but is considered to be different from that of idiopathic bullous pemphigoid （BP）, and varies among DIBP induced by different drugs. DIBP is somewhat different from idiopathic BP in clinical manifestations, but similar to idiopathic BP in clinical laboratory findings. Therefore, clinicians should pay attention to potential causative drugs in patients with DIBP, and stop the use of suspected drugs when necessary.

关 键 词：类天疱疮 大疱性 药用制剂 

分 类 号：R758.66[医药卫生—皮肤病学与性病学]